{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:34:18Z","timestamp":1787776458765,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"\n Objective:<\/jats:title>\n Poor medication adherence, drug interactions, and adverse drug events occur frequently in patients with bipolar I disorder (BD-I), affecting their treatment outcomes. Due to limited research regarding the impact of pharmaceutical care (PC) services in the management of patients with BD-I, this study was designed to assess the role of clinical pharmacist-led interventions on outcomes of BD-I patients.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A prospective randomized clinical trial was designed, and 59 patients were randomly assigned to the intervention group and 48 patients to the control group. Patients in the intervention group were provided with medication therapy management and follow-up services by the clinical pharmacist, whereas the control group only received routine care. Outcomes which were assessed at baseline (before discharge), 1 month, and 3 months after discharge were the Medication Appropriateness Index (MAI), Beck Depression Inventory-II (BDI-II), Young Mania Rating Scale, and World Health Organization Quality of Life, Brief version (WHOQOL-BREF).<\/jats:p>\n <\/jats:sec>\n \n Findings:<\/jats:title>\n \n Endpoint mean changes in MAI scores from baseline were \u22125.25 \u00b1 5.19 and 2.02 \u00b1 3.98 points for the intervention and control groups, respectively (\n P<\/jats:italic>\n < 0.001). Depressive symptoms, measured by the BDI-II, also showed significant improvement in the intervention group; the mean change from baseline to 2\n nd<\/jats:sup>\n follow-up assessment was \u22121.47 \u00b1 7.73 in the intervention group and 1.66 \u00b1 6.42 in the control group (\n P<\/jats:italic>\n = 0.02). Furthermore, the mean change from baseline to 2\n nd<\/jats:sup>\n follow-up in the psychological health domain of the WHOQOL-BREF questionnaire was significantly higher in the intervention group (4.59 \u00b1 17.79) compared with the control group (\u22123.90 \u00b1 12.55) (\n P<\/jats:italic>\n = 0.005).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Our findings reveal that clinical pharmacist-provided services could positively affect outcomes in BD-I patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_52_24","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T06:01:57Z","timestamp":1741672917000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Clinical Pharmacist-led Interventions on the Outcomes of Patients with Bipolar I Disorder: A Randomized Clinical Trial"],"prefix":"10.4103","volume":"13","author":[{"given":"Nazanin","family":"Gorgzadeh","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niayesh","family":"Mohebbi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kheirollah","family":"Gholami","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homayoun","family":"Amini","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali-Akbar","family":"Nejatisafa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Salamzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"R1-20250311","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jyp.2012.09.001","article-title":"The changing face of pharmacy practice and the need for a new model of pharmacy education","volume":"5","author":"Toklu","year":"2013","journal-title":"J Young Pharm"},{"key":"R2-20250311","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/ajhp\/32.6.567","article-title":"Quality of pharmaceutical care in hospitals","volume":"32","author":"Mikeal","year":"1975","journal-title":"Am J Health Syst Pharm"},{"key":"R3-20250311","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11096-014-9933-x","article-title":"Pharmaceutical care: The PCNE definition 2013","volume":"36","author":"Allemann","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"R4-20250311","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/ph16060845","article-title":"Effect of medication therapy management by pharmaceutical care on blood pressure and cardiovascular risk in hypertension: A systematic review, meta-analysis, and meta-regression","volume":"16","author":"de Souza Cazarim","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R5-20250311","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jad.2007.06.014","article-title":"Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders","volume":"108","author":"Judd","year":"2008","journal-title":"J Affect Disord"},{"key":"R6-20250311","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1399-5618.2008.00604.x","article-title":"Quality of life in bipolar disorder patients: A comparison with a general population sample","volume":"10","author":"Guti\u00e9rrez-Rojas","year":"2008","journal-title":"Bipolar Disord"},{"key":"R7-20250311","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jad.2011.10.012","article-title":"Subthreshold symptoms in bipolar disorder: Impact on neurocognition, quality of life and disability","volume":"136","author":"Bonn\u00edn","year":"2012","journal-title":"J Affect Disord"},{"key":"R8-20250311","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40273-014-0250-y","article-title":"Cost-of-illness studies for bipolar disorder: Systematic review of international studies","volume":"33","author":"Jin","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"R9-20250311","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12962-024-00560-1","article-title":"The economic burden of bipolar disorder: A case study in Southern Iran","volume":"22","author":"Shaker","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"key":"R10-20250311","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"R11-20250311","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1176\/ps.2007.58.6.855","article-title":"Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder","volume":"58","author":"Sajatovic","year":"2007","journal-title":"Psychiatr Serv"},{"key":"R12-20250311","doi-asserted-by":"crossref","first-page":"91","DOI":"10.18773\/austprescr.2020.024","article-title":"Lithium therapy and its interactions","volume":"43","author":"Malhi","year":"2020","journal-title":"Aust Prescr"},{"key":"R13-20250311","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/00048674211048410","article-title":"Pharmacist-led interventions for people living with severe and persistent mental illness: A systematic review","volume":"56","author":"Ng","year":"2022","journal-title":"Aust N Z J Psychiatry"},{"key":"R15-20250311","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/0895-4356(92)90144-C","article-title":"A method for assessing drug therapy appropriateness","volume":"45","author":"Hanlon","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R16-20250311","article-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996","journal-title":"San Antonio, TX: Psychological Corporation"},{"key":"R17-20250311","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/da.20070","article-title":"Psychometric properties of a Persian-language version of the beck depression inventory \u2013 Second edition: BDI-II-PERSIAN","volume":"21","author":"Ghassemzadeh","year":"2005","journal-title":"Depress Anxiety"},{"key":"R18-20250311","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: Reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R19-20250311","first-page":"1","article-title":"The World Health Organization Quality of Life (WHOQOL-BREF) questionnaire: Translation and validation study of the Iranian version","volume":"4","author":"Nejat","year":"2006","journal-title":"J Sch Public Health Inst Public Health Res"},{"key":"R20-20250311","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","article-title":"The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization","volume":"41","year":"1995","journal-title":"Soc Sci Med"},{"key":"R21-20250311","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4097\/kjae.2017.70.2.144","article-title":"Central limit theorem: The cornerstone of modern statistics","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"R22-20250311","doi-asserted-by":"crossref","first-page":"e0142011","DOI":"10.1371\/journal.pone.0142011","article-title":"Pharmacist-led medication reviews to identify and collaboratively resolve drug-related problems in psychiatry \u2013 A controlled, clinical trial","volume":"10","author":"Wolf","year":"2015","journal-title":"PLoS One"},{"key":"R23-20250311","doi-asserted-by":"crossref","first-page":"e039747","DOI":"10.1136\/bmjopen-2020-039747","article-title":"Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice","volume":"10","author":"M\u00fcller","year":"2020","journal-title":"BMJ Open"},{"key":"R24-20250311","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/106002809703100501","article-title":"Inappropriate prescribing and health outcomes in elderly veteran outpatients","volume":"31","author":"Schmader","year":"1997","journal-title":"Ann Pharmacother"},{"key":"R25-20250311","first-page":"74","article-title":"Effectiveness of the dader method for pharmaceutical care on patients with bipolar I disorder: Results from the EMDADER-TAB study","volume":"23","author":"Salazar-Ospina","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"R26-20250311","first-page":"218","article-title":"Assessment of the effectiveness of pharmacotherapy follow-up in patients treated for depression","volume":"19","author":"Marques","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"R27-20250311","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1192\/bjp.bp.105.013870","article-title":"Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder","volume":"189","author":"Paykel","year":"2006","journal-title":"Br J Psychiatry"},{"key":"R28-20250311","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3390\/ijms18122679","article-title":"An oldie but goodie: Lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms","volume":"18","author":"Won","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R29-20250311","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.4088\/JCP.v68n0811","article-title":"Mood symptoms, functional impairment, and disability in people with bipolar disorder: Specific effects of mania and depression","volume":"68","author":"Simon","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R30-20250311","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12991-023-00440-7","article-title":"The economic and humanistic burden of bipolar disorder in adults in the United States","volume":"22","author":"Dembek","year":"2023","journal-title":"Ann Gen Psychiatry"},{"issue":"Suppl 3","key":"R31-20250311","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.7075su1c.02","article-title":"Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: The UNITE global survey","volume":"70","author":"McIntyre","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R32-20250311","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40345-017-0078-4","article-title":"Poor quality of life and functioning in bipolar disorder","volume":"5","author":"Sylvia","year":"2017","journal-title":"Int J Bipolar Disord"},{"key":"R33-20250311","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fphar.2017.00722","article-title":"Impact of pharmacist-psychiatrist collaborative patient education on medication adherence and quality of life (QOL) of bipolar affective disorder (BPAD) patients","volume":"8","author":"Mishra","year":"2017","journal-title":"Front Pharmacol"},{"key":"R34-20250311","doi-asserted-by":"crossref","first-page":"s129","DOI":"10.5530\/ijper.51.2s.59","article-title":"The impact of clinical pharmacist lead collaborative care on quality of life of the patients with bipolar disorder: A unicenter prospective, randomization study","volume":"51","author":"Singh","year":"2017","journal-title":"Indian J Pharm Educ Res"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_52_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:09:45Z","timestamp":1787774985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_52_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_52_24","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}